Pharmacological modulation of pressure-overload cardiac hypertrophy: Changes in ventricular function, extracellular matrix, and gene expression

Circulation

Volumn 96, Issue 7, 1997, Pages 2239-2246

  Wong, Kit ^a   Boheler, Kenneth R ^a   Petrou, Mario ^a   Yacoub, Magdi H ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Collagen; Hypertrophy; Pharmacology; Sarcoplasmic reticulum

Indexed keywords

CLENBUTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; ENZYME INDUCTION; GENE EXPRESSION REGULATION; HEART HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART STRESS; MALE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; SARCOPLASMIC RETICULUM;

EID: 0030801835     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.7.2239     Document Type: Article

References (50)

1. Swynghedauw B, Moalic JM, Delcayre C. The origins of cardiac hypertrophy. In: Swynghedauw B, ed. Cardiac Hypertrophy and Failure. London, UK: INSERM/John Libbey Eurotext; 1990:23-50.
2. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
3. Fouad FM, Slominski JM, Tarazi RC. Left ventricular diastolic function in hypertension: relation to left ventricular mass and systolic function. J Am Coll Cardiol. 1984;3:1500-1506.
4. Holubarsch C, Holubarsch T, Jacob R, Medugorac I, Thiedmann K-U. Passive elastic properties of myocardium in different models and stages of hypertrophy. In: Alpert N, ed. Myocardial Hypertrophy and Failure. New York, NY: Raven Press; 1983:323-336.
5. Doering CW, Jalil JE, Janicki JS, Pick R, Aghili S, Abrahams C, Weber KT. Collagen network remodeling and diastolic stiffness of the rat left ventricle with pressure overload hypertrophy. Cardiovasc Res. 1988;22:686-695.
6. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
7. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OHL. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation. 1995;91: 161-170.
8. MacLennan PA, Edwards RH. Effects of clenhuterol and propranolol on muscle mass: evidence that clenbuterol stimulates muscle β-adrenoceptors to induce hypertrophy. Biochem J. 1989;264: 573-579.
9. 2+-ATPase and phospholamban mRNAs during rat heart development. Circ Res. 1995;76:616-625.
10. 2+-ATPase gene in pressure overload-induced cardiac hypertrophy in the rat. Circ Res. 1990;66:554-564.
11. Feldman AM, Weinberg EO, Ray PE, Lorell BH. Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic aortic banding. Circ Res. 1993;73:184-192.
12. 2+-ATPase protein levels. Circ Res. 1995;77:759-764.
13. Cory CR, Grange RW, Houston ME. Role of sarcoplasmic reticulum in loss of load-sensitive relaxation in pressure overload cardiac hypertrophy. Am J Physiol. 1994;266:H68-H78.
14. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991;83:1771-1779.
15. Bruckschlegel G, Holmer SR, Jandeleit K, Grimm D, Muders F, Kromer EP, Riegger GAJ, Schunkert H. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension. 1995;25:250-259.
16. Yang R, Bunting S, Gillett N, Clark R, Jin H. Growth hormone improves cardiac performance in experimental heart failure. Circulation. 1995;92:262-267.
17. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Sacca L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996; 334:809-814.
18. Yacoub MH, Radley-Smith R, McLaurin R. Two-stage operation for anatomical correction of transposition of the greater arteries with intact interventricular septum. Lancet. 1977;1:1275-1278.
19. Borow KM, Arensman FW, Webb C, Radley-Smith R, Yacoub MH. Assessment of left ventricular contractile state after anatomic correction of transposition of the great arteries. Circulation. 1984; 69:106-112.
20. Sievers HH, Lange PE, Onnasch DGW, Radley-Smith R, Yacoub MH, Heintzen PH, Regensburger D, Bernhard A. Influence of the two-stage anatomic correction of simple transposition of the great arteries on left ventricular function. Am J Cardiol. 1985;56:514-519.
21. Boutin C, Wernovsky G, Sanders SP, Jonas RA, Castaneda AR, Colan SD. Rapid two-stage arterial switch operation: evaluation of left ventricular systolic mechanics late after an acute pressure overload stimulus in infancy. Circulation. 1994;90:1294-1303.
22. Wernovsky G, Giglia TM, Jonas RA, Mone SM, Colan SD, Wessel DL. Course in the intensive care unit after 'preparatory' pulmonary artery banding and aortopulmonary shunt placement for transposition of the great arteries with low left ventricular pressure. Circulation. 1992;86(suppl II):II-133-II-139.
23. Bartosova D, Chvapil M, Korecky B, Poupa O, Rakusan K, Turek Z, Vizek M. The growth of the muscular and collagenous parts of the rat heart in various forms of cardiomegaly. J Physiol. 1969;200: 285-295.
24. 2+-ATPase and phospholamban mRNA expression in response to pressure overload and thyroid hormone. Proc Natl Acad Sci U S A. 1989;86:2966-2970.
25. 2+-ATPase in the rat heart. J Biol Chem. 1988;263:6941-6944.
26. Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J Jr. Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest. 1995;95:619-627.
27. Petrou M, Wynne DG, Boheler KR, Yacoub MH. Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. Circulation. 1995; 92(suppl II):II-483-II-489.
28. Wong K, Boheler KR, Bishop J, Petrou M, Yacoub MH. Functional, morphological and molecular features of clenbuterol-induced cardiac hypertrophy. Cardiovasc Res. In press.
29. Benjamin IJ, Jalil JE, Tan LB, Cho K, Weber KT, Clark WA. Isoproterenol-induccd myocardial fibrosis in relation to myocyte necrosis. Circ Res. 1989;65:657-670.
30. 31P-NMR study. Biochim Biophys Acta. 1990;1055:107-116.
31. Izumo S, Lompre AM, Matsuoka R, Koren G, Schwanz K. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy: interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest. 1987;79:970-977.
32. Curtis MJ, MacLeod BA, Tahrizchi R, Walker MJA. An improved perfusion apparatus for small animals. J Pharmacol Methods. 1986; 15:87-94.
33. Weber KT, Janicki JS, Reeves RC, Hefner LL. Factors influencing left ventricular shortening in isolated canine heart. Am J Physiol. 1976;230:419-426.
34. Campa JS, McAnulty RJ, Laurent GJ. Application of high-pressure liquid chromatography to studies of collagen production by isolated cells in culture. Anal Biochem. 1990;186:257-263.
35. Laurent GJ, Cockerill P, McAnulty RJ, Hastings JB. A simplified method for quantification of the relative amounts of type I and type III collagen in small tissue samples. Anal Biochem. 1981;133: 301-312.
36. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
37. 2+-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest. 1990;85:305-309.
38. Collins P, Billings CG, Barer GR, Daly JJ, Jolly A. Quantization of isoproterenol-induced changes in the ventricular myocardium. Cardiovasc Res. 1975;9:797-806.
39. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res. 1990;67:1355-1364.
40. Alpert NR, Mulieri LA. Increased myothermal economy of isometric force generation in compensated cardiac hypertrophy induced by pulmonary artery constriction in the rabbit. Circ Res. 1982;50:491-500.
41. Boheler KR, Schwartz K. Gene expression in cardiac hypertrophy. Trends Cardiovasc Med. 1992;2:176-182.
42. Palmer RM, Delday MI, McMillan DN, Noble BS, Bain P, Maltin CA. Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats. Br J Pharmacol. 1990;101:835-838.
43. Sillence MN, Matthews ML, Spiers WG, Pegg GG, Lindsay DB. Effects of clenbuterol, ICI118551 and sotalol on the growth of cardiac and skeletal muscle and on β2-adrenoceptor density in female rats. Arch Pharmacol. 1991;344:449-453.
44. Cartana J, Stock MJ. Effects of digoxin on the anabolic response to clenbuterol. Metabolism. 1994;43:959-964.
45. Yang YT, McElligott MA. Multiple actions of β-adrenergic agonists on skeletal muscle and adipose tissue. J Biochem. 1989;261:1-10.
46. Hayes VY, Isackson PJ, Fabrazzo M, Follesa P, Mocchetti I. Induction of nerve growth factor and basic fibroblast growth factor mRNA following clenbuterol: contrasting anatomical and cellular localization. Exp Neurol. 1995;132:33-41.
47. Whitelaw PF, Hesketh JE. Expression of c-myc and c-fos in rat skeletal muscle: evidence for increased levels of c-myc mRNA during hypertrophy. J Biochem. 1992;281:143-147.
48. Beermann DH, Butler WR, Hogue DE, Fishell VK, Dalrymple RH, Ricks CA, Scanes CG. Cimaterol-induced muscle hypertrophy and altered endocrine status in lambs. J Anim Sci. 1988;66:1320.
49. 2-adrenergic agonists on body composition and protein synthesis in the rat. Biosci Rep. 1984;4:83-91.
50. Dupont-Versteegden EE, Katz MS, McCarter RS. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice. Muscle Nerve. 1995;18:1447-1459.